Psoriasis clinical trials

The registry lists 2,028 studies for Psoriasis across more than 10 countries. 275 are recruiting or about to start. 1,780 of them are mainly about Psoriasis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09. Counting its narrower condition Arthritis, Psoriatic too: 2,500 studies, 377 open.

ClinicalTrials.gov finds 2,577 studies for Psoriasis. How that becomes 2,027 here

This page counts the studies the registry files under Psoriasis, and those it files under no condition that list Psoriasisthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

2,577Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
−466Filed under a narrower condition, counted on its own pageArthritis, Psoriatic 466
−56List Psoriasis as a condition, but the registry did not file them under itMost often written as “Plaque Psoriasis” (20), “Psoriasis Vulgaris” (16), and “Chronic Plaque Psoriasis” (4). The registry filed them under other conditions only, most often Pruritus (11) and Skin Diseases (8).
−28Match it another way26 name it in the title and 2 in a keyword.
2,027The count on this page558 of them list Psoriasis in their own words; the registry filed them under no condition.

Get an email when these change. Save the Psoriasis studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 1,374
Recruiting: 174
Status unknown: 152
Terminated: 107
Not yet recruiting: 92
Active, not recruiting: 66

Phase

Phase 2: 442
Phase 3: 425
Phase 1: 270
Phase 4: 261
Early Phase 1: 22

Where

United States: 763
Canada: 302
Germany: 299
China: 206
France: 185
Poland: 166

Who runs them

LEO Pharma (79) · Novartis Pharmaceuticals (64) · Amgen (61) · AbbVie (51) · Pfizer (50) · Bristol-Myers Squibb (40) · Eli Lilly and Company (31) · Janssen Research & Development, LLC (30)

What is being tested here

Drugs under test in Psoriasis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Methotrexate	7	6	24
Guselkumab	5	10	23
Adalimumab	4	18	37
Apremilast	4	13	33
Ustekinumab	4	14	26
Deucravacitinib	4	9	21
Tofacitinib	4	9	18
Secukinumab	3	22	42
Bimekizumab	3	8	17
HS-10374	3	1	5

Drug classes tested here JAK inhibitors 11 open · Tyrosine kinase inhibitors (TKIs) 10 open · Antimetabolites 7 open · GLP-1 receptor agonists 3 open · Corticosteroids 2 open

Coming up

52phase 3 studies under way

98studies finish main data collection within a year11 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Nov 2026Study to Assess Efficacy, Safety and Tolerability of a Nail Patch in Patients With Nail Fragility, Mychosis, Psoriasis · Phase 3 · Wooshin Labottach Co., Ltd.
Nov 2026A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque Psoriasis · Phase 3 · Zhejiang Wenda Pharma Technology LTD.
Dec 2026Efficacy of Crisaborole 2% Ointment Versus Tacrolimus 0.1% Ointment in the Treatment of Intertriginous and/or Anogenital Psoriasis. · Phase 3 · Cairo University
Jan 2027Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant) · Phase 3 · Wake Forest University Health Sciences
Jan 2027A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of RSS0393 Ointment in Adult Patients With Plaque Psoriasis. · Phase 3 · Reistone Biopharma Company Limited
Mar 2027A Study of HS-20137 in Participants with Moderate-to-severe Plaque Psoriasis · Phase 3 · Hansoh BioMedical R&D Company
Apr 2027A Phase III Study of SYHX1901 Tablets in the Treatment of Moderate to Severe Plaque Psoriasis · Phase 3 · CSPC Ouyi Pharmaceutical Co., Ltd.
May 2027A Study of Zasocitinib in Adults With Non-pustular Palmoplantar Psoriasis · Phase 3 · Takeda
Jul 2027A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis · Phase 3 · InventisBio Co., Ltd
Jul 2027Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis · Phase 3 · InventisBio Co., Ltd

Who these studies take

Of the 174 Psoriasis studies recruiting now, 91 (52%) set no upper age limit and 67 (39%) stop at 75 or younger. 25 (14%) take children under 18. 4 (2%) are for women only and 0 (0%) for men only; 40 (23%) take healthy volunteers.

Recruiting studies that take each age, of 174
Age	Women	Men
10	17 (10%)	15 (9%)
18	163 (94%)	160 (92%)
30	167 (96%)	164 (94%)
40	169 (97%)	165 (95%)
50	168 (97%)	165 (95%)
65	158 (91%)	155 (89%)
75	127 (73%)	124 (71%)
85	103 (59%)	100 (57%)

Across all 2,028 studies, recruiting or not: 38% stop at 75 or younger and 21% at 65; 11% take children; 1% are for women only and 2% for men only; 17% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Psoriasis studies take

Of 227 phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	10 mo5–17 · 155 studies	10 mo4–16 · 137 studies	—
Phase 1/2	9 mo3–21 · 15 studies	—	—
Phase 2	14 mo9–23 · 174 studies	12 mo9–20 · 145 studies	36 mo20–43 · 29 studies
Phase 3	15 mo10–26 · 227 studies	15 mo10–26 · 217 studies	—
Phase 4	23 mo12–43 · 115 studies	22 mo11–29 · 40 studies	25 mo14–49 · 75 studies
Interventional, no phase	19 mo8–38 · 134 studies	—	21 mo10–41 · 115 studies
Observational	37 mo23–93 · 173 studies	37 mo23–74 · 81 studies	43 mo17–119 · 92 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 11, 2026.

Show 4 more

Comparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or Immediate-release FormulationNov 2, 2026NCT07908641
Efficacy and Flexibility of Tildrakizumab Treatment in Patients With Moderate-to-severe Plaque Psoriasis and High Disease BurdenOct 28, 2026NCT07900659
Efficacy of Crisaborole 2% Ointment Versus Tacrolimus 0.1% Ointment in the Treatment of Intertriginous and/or Anogenital Psoriasis.Oct 23, 2026NCT07892339
Definition of Novel Optoacoustic Biomarkers of Psoriasis and Psoriatic ArthritisOct 21, 2026NCT07885345

Studies

Recruiting first, then most recently updated. Showing 50 of 2,028. Browse all 2,028 → or search them.